ValuentumAd

Official PayPal Seal














Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Feb 11, 2024
Eli Lilly’s Shares Have More Than Doubled During the Past 52 Weeks
Image: Eli Lilly’s shares have been on a tear these past few years. On February 6, Eli Lilly reported excellent fourth-quarter results that showed revenue and non-GAAP earnings per share coming in better than expectations. The company’s fourth-quarter results were bolstered by sales of diabetes and weight-loss drug Mounjaro, which saw sales in the quarter leap to ~$2.2 billion from ~$279 million in the year ago period. We continue to be in awe of the sales momentum behind GLP-1 receptor agonists, and the opportunity continues to be robust, despite already rapid sales acceleration. Though Eli Lilly trades at a premium to the high end of our fair value estimate range, we may be low in our expectations of the company’s ability to tap this lucrative market in the longer run, and shares may still be attractive to the risk-seeking aggressive growth investor.
Feb 9, 2024
Earnings Roundup: PEP, DIS, ARM, PM
Image Source: Arm Holdings. Pepsi issued an outlook for 2024 that came in lower than what the Street was expecting, but we like the diversification of having a strong brand entity such as Pepsi in the Best Ideas Newsletter portfolio. Disney is working hard to get back on track, and cost-cutting efforts have significantly helped its free cash flow generation. The firm is buying back stock, too, and recently upped its semi-annual dividend payout by 50%. Arm Holdings plc surprised the market in a big way, sending shares almost 50% higher following the report. The company's lucrative royalty business model and attractive exposure to artificial intelligence has investors extremely excited. Philip Morris is targeting strong organic revenue growth in 2024 thanks in part to Zyn growth, and we like the strong foundation that its free cash flow provides in supporting its dividend.
Feb 9, 2024
Dividend Increases/Decreases for the Week of February 9
Let's take a look at firms raising/lowering their dividends this week.
Feb 4, 2024
Earnings Roundup: MO, EPD, SBUX, CLX, HON
Image: Starbucks’ international store growth potential remains robust. Image Source: Starbucks. High-yielding tobacco giant Altria offered an outlook through 2028 that spoke to continued robust earnings and dividend-per-share expansion. Enterprise Products Partners, now a Dividend Aristocrat, is handling record volumes through its pipeline network, and the firm is investing heavily to drive improved long-term cash flow trends. Starbucks recently disappointed on a number of metrics, but the company's margin and earnings performance remains excellent, as is its international store growth opportunities. Clorox has recovered nicely from a recent cyberattack, and the firm is now forecasting adjusted earnings per share growth in fiscal 2024. We're monitoring its cash flow trends closely, however. Honeywell is targeting tremendous free cash flow growth in 2024 thanks to continued strength in its commercial aerospace operations.
Feb 2, 2024
Earnings Roundup: ABBV, CVX, NYCB, XOM
Image: Unrealized losses continue to mount for banking entities due to the Fed's rate-hiking cycle. "Unrealized losses on securities totaled $683.9 billion in third quarter, up $125.5 billion (22.5 percent) from the prior quarter, primarily due to an increase in mortgage rates that reduced the value of mortgagebacked securities. Unrealized losses on held-to-maturity securities totaled $390.5 billion in the third quarter, while unrealized losses on available-for-sale securities totaled $293.5 billion." -- Image Source: FDIC Quarterly.AbbVie is facing pressure from declining sales of Humira, but the company's long-term outlook looks fine to us bolstered by promising growth of Skyrizi and Rinvoq. Chevron put up mixed fourth-quarter 2023 results, but its free cash flow easily covers its dividend payout. We've grown cautious on Chevron due to its deal making, however. New York Community Bancorp is provisioning for greater credit losses, while its net interest margin is under pressure. The bank recently slashed its payout, and we continue to reiterate why we don't like the dividends of banking firms. Exxon Mobil put up an excellent 2023, and while the firm's dividend is in great shape, we no longer are pursuing new energy-related ideas in the newsletter portfolios at this time.
Feb 2, 2024
Dividend Increases/Decreases for the Week of February 2
Let's take a look at firms raising/lowering their dividends this week.
Feb 2, 2024
Big Cap Tech and Large Cap Growth Continue to Lead Market Higher
Image Source: Marco Pakoeningrat. We continue to like the areas of big cap tech and large cap growth as the top firms in these areas have strong cash-based sources of intrinsic value: net cash on the balance sheet and strong expected future free cash flow generation. After the close February 1, the market received the quarterly earnings reports from Meta Platforms, Amazon, and Apple, and we were pleased by the trio’s performance during the calendar fourth quarter. We maintain our long-held view that big cap tech and large cap growth will continue to lead the market higher, and we continue to overweight these areas in the newsletter portfolios.
Jan 28, 2024
What Causes Fair Value Estimates to Change?
Image: A screenshot of the discounted cash-flow learning tool for individual investors. So you noticed a fair value estimate changed, and you weren’t sure why? This article is for you.
Jan 28, 2024
14%+ Yielding AGNC Investment May Be Worth a Trade
Image: AGNC Investment has managed to level out its dividend payments following a few years of dividend cuts. We’ve never been fans of the mortgage REIT arena, but some stabilization in the marketplace is likely to be expected, allowing a window for investors to generate what could be a very nice dividend yield on an otherwise very risky, leveraged area. As of the end of last year, AGNC Investment Corp. ended the year with $8.70 in tangible net book value, which increased 7.7% from September. Though the stock trades at a slight premium to its tangible net book value at the time of this writing, management’s positive commentary indicates to us that tangible book value may be poised to rise nicely given a more sanguine backdrop. AGNC Investment Corp. is not for long-term investors, but with its 14%+ dividend yield, the stock could make for a very nice high yield dividend income trade, in our view.
Jan 28, 2024
Earnings Roundup: V, INTC, HUM, PYPL
Image: Visa’s operating margins are phenomenal. Image Source: Visa. Visa's first-quarter fiscal 2024 results were solid, and the firm noted that consumer spending remains resilient, paving the way for what we think will be a strong year. Intel's outlook for 2024 left a lot to be desired, and its balance sheet coupled with free cash flow burn should give more conservative investors pause. Humana's earnings outlook for 2024 spoke of considerable cost pressures, and we think this is yet another data point that the near term will be difficult for many health insurers as pent-up demand for procedures delayed during the pandemic begin to materialize. PayPal's stock remains in the dog house, and while its recently-announced innovations are great, consumer sentiment remains poor on the name.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.